Navigation Links
Par Pharmaceutical Reports Third-Quarter 2007 Results
Date:12/20/2007

5 million, representing the premium paid, was charged to R&D in the third quarter.

Third-quarter selling, general and administrative (SG&A) expense decreased 15.3 percent to $33.9 million. The decrease in 2007 SG&A expense was primarily due to the non-recurrence of severance costs incurred in 2006 for executives of $7.1 million, partially offset by increased costs associated with the expansion of finance and accounting functions and increased professional costs related to the Company's restatement of prior periods.

2007 Financial Outlook

Par has adjusted its previously announced guidance for full-year 2007 earnings per diluted share of $1.45-$1.50 from $1.35-$1.50. Total net revenue is expected to be between $760-$780 million. SG&A is expected to be $130-$133 million, including approximately $2 million in severance costs. Research and development cost is projected to be in the range of $75-$80 million, including approximately $19 million in branded milestone payments. Total projected expenses for the full-year include approximately $18-20 million of share-based compensation and $24-$26 million of depreciation and amortization expenses. Adjusting for non-GAAP items highlighted on the summary of estimated operating results for full year 2007 at the end of this press release, full year earnings per diluted share is projected to be $1.50-$1.55.

Stock Repurchase Program

Since October 1, 2007, Par has repurchased 1,643,094 shares of its common stock at a total cost of $31.5 million. On September 28, 2007, Par announced that its Board of Directors had authorized the repurchase of up to $75 million of the Company's common stock.

Conference Call

Par has scheduled a conference call for Thursday, December 20, 2007 at 9:00 am EST to discuss results for the third quarter of 2007. Par invites investors and the general public to listen to a webcast of the conference call. Access to the live webcast can be made via the Company's webs
'/>"/>

SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine news :

1. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
4. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
6. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
8. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
9. Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts Meeting September 28, 2007
10. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Pharmaceutical Manufacturing Quality: Optimizing Your Internal Process for FDA Compliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... 2014 Horse Sense & Sensitivity ... to special needs individuals in the Jacksonville area, will ... 15 from 10-2:00 p.m. at Bailey's Farm (2202 Bishop ... the public and is designed to raise awareness and ... the HSS Round-Up is free. Ticket purchases will be ...
(Date:10/30/2014)... The annual meeting of The North ... on Saturday, October 18th, marking the end of the ... NAMS is North America’s leading non-profit organization dedicated to ... women during midlife and beyond through an understanding of ... thought leaders from fields as varied as gynecology, sociology, ...
(Date:10/30/2014)... Amy Norton HealthDay ... Exposure to a common plastics, chemical during pregnancy may have ... hints. Researchers found that baby boys born to moms ... have a shorter anogenital distance -- the space between the ... and it,s considered a marker of exposure to androgens ("male" ...
(Date:10/30/2014)... WEDNESDAY, Oct. 29, 2014 (HealthDay News) -- A new ... life-threatening meningococcal disease was approved by the U.S. Food ... to protect people between the ages of 10 and ... meningitidis serogroup B bacteria. The bacteria can ... the spinal cord and brain. It is a leading ...
(Date:10/29/2014)... cancer medications are linked with an increased risk of ... failure or prior heart attacks. Published in BJU ... weigh the benefits and risks of the drugs. ... male hormones in the body to prevent them from ... prostate cancer. Despite its anticancer effects, ADT has been ...
Breaking Medicine News(10 mins):Health News:Horse Sense & Sensitivity, Jacksonville Non-profit, To Hold 2nd Annual Round-Up 2Health News:Highlights from The North American Menopause Society 25th Annual Meeting 2Health News:Highlights from The North American Menopause Society 25th Annual Meeting 3Health News:Plastics' Chemical May Affect Baby Boys' Genital Development 2Health News:Plastics' Chemical May Affect Baby Boys' Genital Development 3Health News:FDA Approves New Vaccine to Protect Against Meningitis 2Health News:Prostate cancer medications linked with increased risk of heart-related deaths in men with cardiovascular problems 2
... released important information about epilepsy and seizure,disorders to dispel ... Edward Kennedy (D-Mass)., Senator Kennedy, 76, one of ... a seizure on Saturday. A seizure is a,disturbance in ... Americans,will have a single seizure at some point in ...
... foods, such as bread, pasta, often goes unnoticed , , ... lead to improved diagnosis and treatment of celiac disease, ... meeting in San Diego. , Celiac disease, which ... an autoimmune disorder in the small intestine triggered by ...
... developing reliable genetic tests to guide lung cancer treatment ... recently evaluated the ability of five high-risk genetic profiles, ... recur in patients whose non-small cell lung cancer was ... findings at the American Thoracic Societys 2008 International Conference ...
... 19 Roche Diagnostics today announced,that Quest Diagnostics ... of,diagnostic testing, information and services, has signed a ... TaqMan(R) HIV-1 Test for,HIV viral load testing., ... effects of,antiretroviral therapy by measuring changes in HIV-1 ...
... Risks and Identifies ... Approaches to Manage Those Risks, SCHAUMBURG, Ill., May 19 ... of gas, inflation is affecting every,American. Among the largest groups affected ... current retirees who are experiencing,soaring costs in a volatile economy., ...
... 19 On May 13, 2008, the Cancer,Prevention Coalition, ... FDA. This updates scientific information detailed in a,November 17, ... It also,documents prior knowledge of the FDA and industry ... basis of the 2008 Petition is detailed in 11 ...
Cached Medicine News:Health News:The Epilepsy Foundation Sheds Light on Seizures 2Health News:Advances Aid Treatment, Diagnosis of Celiac Disease 2Health News:Advances Aid Treatment, Diagnosis of Celiac Disease 3Health News:Will lung cancer recur? A genetic test may provide the answer 2Health News:Quest Diagnostics Chooses Roche's Fully Automated, Real-Time HIV-1 Viral Load Monitoring Test For Its Customers in Laboratories Nationwide 2Health News:Inflation Ranks as Today's Top Retirement Concern 2Health News:Inflation Ranks as Today's Top Retirement Concern 3Health News:Inflation Ranks as Today's Top Retirement Concern 4Health News:Petition Seeking a Cancer Warning on Cosmetic Talc Powder Products 2
(Date:10/30/2014)... -- CVS Health (NYSE: CVS ) announced today ... regional health systems to enhance access to high-quality, affordable health ... Health System in Alabama ; Community Health ... Pennsylvania , Northwest Medical Center, including Oro Valley ... in Tennessee ; and Premier Health in ...
(Date:10/30/2014)...  CytRx Corporation (NASDAQ: CYTR ), ... oncology, today announced an upcoming presentation highlighting its ... The presentation, titled, "Drug Conjugates Bind Covalently to ... Sant P. Chawla , M.D., F.R.A.C.P., Director ... of the Company,s ongoing global, pivotal Phase 3 ...
(Date:10/30/2014)... Oct. 30, 2014 Today, DripDrop, the ... that it was awarded a two-year contract, effective ... company that serves the more than 100,000 members ... Association and Provista.  DripDrop also ... from member hospitals who attended the recent Novation ...
Breaking Medicine Technology:CVS Health Announces New Clinical Affiliations with Leading Regional Health Systems 2CVS Health Announces New Clinical Affiliations with Leading Regional Health Systems 3CVS Health Announces New Clinical Affiliations with Leading Regional Health Systems 4CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 2CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 3CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 4DripDrop Partners With Novation To Help Hospitals Address I.V. Saline Solution Shortages; ORS Product Used For Ebola Outbreak 2DripDrop Partners With Novation To Help Hospitals Address I.V. Saline Solution Shortages; ORS Product Used For Ebola Outbreak 3DripDrop Partners With Novation To Help Hospitals Address I.V. Saline Solution Shortages; ORS Product Used For Ebola Outbreak 4
... ,, LAIYANG, China , July 9 /PRNewswire-Asia-FirstCall/ -- ... present at the Global Hunter Securities,China Investment Conference, which takes place July 11-13, 2010 ... , , ... 2010 , , , ...
... July 8 Sysmex, a global leader ... technology, today announced a three-year, dual source urinalysis ... purchasing/leasing access to Sysmex automated urine particle analyzers, ... for Amerinet members will be provided through Sysmex ...
Cached Medicine Technology:Jiangbo Pharmaceuticals to Attend Global Hunter Securities China Conference 2Jiangbo Pharmaceuticals to Attend Global Hunter Securities China Conference 3Sysmex America Announces Amerinet Urinalysis Contract 2Sysmex America Announces Amerinet Urinalysis Contract 3
IMMCO ANA Elisa meets the guidelines for the laboratory diagnosis and monitoring of systemic autoimmune rheumatic diseases intended for the use of clinical pathologists and laboratory physicians....
An enzyme-linked immuno-sorbent assay for the detectionand quantitation of anti-tissue Transglutaminase in serum of patients with Celiac Disease and Dermatitis Herpetiformis....
Jerome Halo Traction Units provide optimum immobilization for unstable injuries of the spine. The Generation 80 superstructure is available with either 2-point (serrated disk), or 3-point (flexion/ex...
... Boston Scoliosis Brace™ for neuromuscular ... a lightweight, soft, and easy ... maximum comfort. The Soft ... of non-cracking orthopedic grade copolymer ...
Medicine Products: